Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment
- PMID: 23241943
- PMCID: PMC3922978
- DOI: 10.1097/FPC.0b013e32835ca260
Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment
Abstract
Objective: To examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia.
Materials and methods: We performed GWAS to search for genetic variation affecting treatment response. The analysis sample included 738 patients with schizophrenia, successfully genotyped for ∼492k single nucleotide polymorphisms (SNPs) from the Clinical Antipsychotic Trial of Intervention Effectiveness. Outcomes included both clinician and patient report of illness severity on global impression scales, the clinical global impression severity scale and patient global impression, respectively. Our criterion for genome-wide significance was a prespecified threshold ensuring that, on average, only 10% of the significant findings are false discoveries.
Results: Thirteen SNPs reached genome-wide significance. The top findings indicated three SNPs in PDE4D, 5q12.1 (P=4.2×10, 1.6×10, 1.8×10), mediating the effects of quetiapine on patient-reported severity and an additional three SNPs in TJP1, 15q13.1 (P=2.25×10, 4.86×10, 4.91×10), mediating the effects of risperidone on patient-reported severity. For clinician-reported severity, two SNPs in PPA2, 4q24 (P=3.68×10, 5.05×10), were found to reach genome-wide significance.
Conclusion: We found evidence of both a novel and a consistent association when examining the results from the patient and clinician ratings, suggesting that different raters may capture unique facets of schizophrenia. Although our findings require replication and functional validation, this study shows the potential of GWAS to discover genes that potentially mediate treatment response of antipsychotic medication.
Figures
References
-
- van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–45. - PubMed
-
- Guy W. DHEW Publ No ADM 76-338. National Institute of Mental Health; Rockville, MD: 1976. Clinical Global Impressions ECDEU Assesment Manual fo Psychopharmacology, Revised; pp. 218–22.
-
- Murray EJ. Measurement issues in the evaluation of psychopharmacological therapy. In: Fisher S, Greenberg RP, editors. The limits of biological treatments for psychological distress: Comparisons with psychotherapy and placebo. Hillsdale, NJ, England: Lawrence Erlbaum Associates, Inc; 1989. pp. 39–67.
-
- Lindstrom E, Jedenius E, Levander S. A symptom Self-rating Scale for Schizophrenia (4S): Psychometric properties, reliability and validity. Nordic Journal of Psychiatry. 2009;63(5):368–U4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
